CG
ARQT icon

Cutler Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Cutler Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-800
Closed -$17K – 4878
2022
Q2 		$17K Buy
+800
New +$16.4K ﹤0.01% 2783

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Cutler Group's ARQT Position: Q3 2022 in Review

Cutler Group sold out of Arcutis Biotherapeutics (ARQT) in Q3 2022, closing a stake of 800 shares — an estimated $17K sold.

Cutler Group first reported a position in ARQT in Q2 2022 and held it in 1 quarter. The position peaked at $17K in Q2 2022. 139 funds tracked by Wall St. Rank hold ARQT as of Q3 2022.

  • Cutler Group reported no remaining Arcutis Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 800 Arcutis Biotherapeutics shares in Q3 2022, an estimated $17K.
  • Cutler Group first reported a position in Arcutis Biotherapeutics in Q2 2022 and held it in 1 quarter.
  • Cutler Group's Arcutis Biotherapeutics position peaked at $17K in Q2 2022.
  • 139 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.